• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio

    BIOSPACE

    Roche Becomes MASH Player via $3.5 B Deal for 89bio, Ph. 3 Drug

    GLOBENEWSWIRE

    89bio Reports Q2 2025 Financial Results and Corporate Updates

    GLOBENEWSWIRE

    89bio Reports Q4 and Full Year 2024 Financial Results

    GLOBENEWSWIRE

    89bio Presents Pegozafermin Data, Non-Invasive Test in MASH

    GLOBENEWSWIRE

    89bio Presents New Analyses From Enliven Phase 2b Trial for MASH

    GLOBENEWSWIRE

    89bio Announces Inducement Grants Under Nasdaq Listing Rule

    GLOBENEWSWIRE

    89bio Initiates Phase 3 Pegozafermin ENLIGHTEN-Cirrhosis Trial In MASH

    GLOBENEWSWIRE

    89bio KOL Webinar On Pegozafermin In Advanced MASH

    GLOBENEWSWIRE

    89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

    GLOBENEWSWIRE

    89bio Receives EMA Status for Pegozafermin in the Treatment of MASH

    GLOBENEWSWIRE

    89bio wins EMA priority status for MASH candidate pegozafermin

    PHARMACEUTICAL TECHNOLOGY

    89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin

    GLOBENEWSWIRE

    89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin

    GLOBENEWSWIRE

    89bio Announces Data from the ENLIVEN Phase 2b Trial of Pegozafermin

    GLOBENEWSWIRE

    89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin

    GLOBENEWSWIRE

    89bio Announces FDA has Granted Breakthrough Designation for Pegozafermin

    GLOBENEWSWIRE

    Data from 89bio ENLIVEN Ph2b Trial of Pegozafermin (NASH) Published in The NEJM

    GLOBENEWSWIRE

    89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin

    GLOBENEWSWIRE

    89bio Phase 2b ENLIVEN Trial of Pegozafermin in NASH Achieved Significance

    GLOBENEWSWIRE

    89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin

    GLOBENEWSWIRE

    89bio to Present Pegozafermin Data in SHTG from PII ENTRIGUE Study

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.